RYTM Stock Overview
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rhythm Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$50.00 |
| 52 Week High | US$53.92 |
| 52 Week Low | US$20.97 |
| Beta | 2.04 |
| 11 Month Change | 1.94% |
| 3 Month Change | 38.08% |
| 1 Year Change | 91.94% |
| 33 Year Change | 293.39% |
| 5 Year Change | 122.02% |
| Change since IPO | 66.67% |
Recent News & Updates
Recent updates
Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)
Jun 12Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates
May 09
Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon
May 05Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22
Mar 03Rhythm Pharmaceuticals: Action Too Specific
Feb 23Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price
Jan 08We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely
Nov 03We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate
Jul 23Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing
Jun 17Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates
May 05Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans
Apr 01An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued
Dec 15We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully
Oct 24Rhythm Pharmaceuticals: Revisiting The Investment Thesis
Oct 10Rhythm Pharmaceuticals announces $100M stock offering; shares fall 12% after hours
Sep 14Rhythm Pharma's Imcivree drug gets expanded approval by European Commission for BBS
Sep 06Industry Analysts Just Made An Incredible Upgrade To Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenue Forecasts
Aug 08Rhythm Pharmaceuticals Q2 2022 Earnings Preview
Aug 01Rhythm Pharma gains as NICE recommends obesity drug
Jul 18Is Rhythm Pharmaceuticals (NASDAQ:RYTM) In A Good Position To Deliver On Growth Plans?
Jun 04Shareholder Returns
| RYTM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.2% | 0.7% | 0.1% |
| 1Y | 91.9% | 15.8% | 24.9% |
Return vs Industry: RYTM exceeded the US Biotechs industry which returned 15.9% over the past year.
Return vs Market: RYTM exceeded the US Market which returned 25.9% over the past year.
Price Volatility
| RYTM volatility | |
|---|---|
| RYTM Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: RYTM's share price has been volatile over the past 3 months.
Volatility Over Time: RYTM's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 226 | David Meeker | rhythmtx.com |
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders.
Rhythm Pharmaceuticals, Inc. Fundamentals Summary
| RYTM fundamental statistics | |
|---|---|
| Market cap | US$2.82b |
| Earnings (TTM) | -US$260.73m |
| Revenue (TTM) | US$101.78m |
30.0x
P/S Ratio-11.7x
P/E RatioIs RYTM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RYTM income statement (TTM) | |
|---|---|
| Revenue | US$101.78m |
| Cost of Revenue | US$11.40m |
| Gross Profit | US$90.38m |
| Other Expenses | US$351.12m |
| Earnings | -US$260.73m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.26 |
| Gross Margin | 88.80% |
| Net Profit Margin | -256.17% |
| Debt/Equity Ratio | 60.4% |
How did RYTM perform over the long term?
See historical performance and comparison